The 20 Best Renal Cell Carcinoma (RCC) Doctors Near Me

Rimas Lukas is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 24 years. Dr. Lukas is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy. Dr. Lukas is board certified in American Board Of Psychiatry And Neurology - Neurology (Certified).

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Carducci is board certified in American Board Of Internal Medicine.

David Mcdermott is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine.

Dr. Michael Pishvaian is the director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the Greater Washington Area and an associate professor at the School of Medicine. Dr. Pishvaian is a fellowship-trained gastrointestinal oncologist specializing in pancreatic and refractory colorectal cancers. He is committed to precision medicine and provides his patients with the most appropriate and advanced level of care. He conducts all phases of clinical trials for all GI cancers and enrolls qualifying patients. Click here to learn more about oncology clinical trials the Greater Washington Area. Dr. Pishvaian is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Pishvaian is board certified in American Board Of Internal Medicine.

Roger Cohen is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Endoscopy. Dr. Cohen is board certified in Medical Oncology, 1993, Hematology, 1986, and Internal Medicine, 1984. Dr. Cohen is currently accepting new patients.

Ashley Sumrall is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Sumrall is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Glioma, Gliosarcoma, Brain Tumor, and Astrocytoma. Dr. Sumrall is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine, Medical Oncology. Dr. Sumrall is currently accepting new patients.

Antonio Gasbarrini practices practicing medicine in Rome, Italy. Gasbarrini is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). They are also highly rated in 70 other conditions, according to our data. Their clinical expertise encompasses Small Bowel Bacterial Overgrowth, Viral Gastroenteritis, Helicobacter Pylori Infection, Liver Transplant, and Endoscopy.

Thorvardur Halfdanarson is an Oncologist practicing medicine in Rochester, Minnesota. Dr. Halfdanarson is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Hepatectomy.

Dafydd Evans practices practicing medicine in Manchester, United Kingdom. Evans is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). They are also highly rated in 39 other conditions, according to our data. Their clinical expertise encompasses Schwannomatosis, Neurofibromatosis Type 2 (NF2), Acoustic Neuroma, Oophorectomy, and Salpingo-Oophorectomy.

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology.

Giuseppe Curigliano practices practicing medicine in Milan, Italy. Mr. Curigliano is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Mastectomy, and Tissue Biopsy.

Jaume Capdevila practices practicing medicine in Barcelona, Spain. Capdevila is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). They are also highly rated in 12 other conditions, according to our data. Their clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Thyroid Cancer, Medullary Thyroid Carcinoma, and Appendectomy.

Jeffrey Sosman is an Oncologist practicing medicine in Chicago, Illinois. Dr. Sosman is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Melanoma, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

David Hong is an Oncologist practicing medicine in Cary, North Carolina. Dr. Hong is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 60 other conditions, according to our data. His clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Adult Soft Tissue Sarcoma, Lung Cancer, Posterior Fossa Decompression, and Thrombectomy.

Kathleen Moore is an Obstetrics and Gynecologist practicing medicine in Oklahoma City, Oklahoma. Dr. Moore is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Hysterectomy, and Tissue Biopsy.

Naiyer Rizvi is an Oncologist practicing medicine in New York, New York. Dr. Rizvi is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery.

Razelle Kurzrock is an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Kurzrock is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 37 other conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, and Tissue Biopsy.

Denise Yardley is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Yardley is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast. Dr. Yardley is currently accepting new patients.